Clinical Importance of estrogen reactivity in Hormone Receptor Positive HER2-Negative Breast Cancer

被引：0
|
作者：
Takeshita, Takashi [1 ]
Iwase, Hirotaka [1 ]
Takabe, Kazuaki [2 ]
机构：
[1] Kumamoto City Hosp, Kumamoto, Japan
[2] Roswell Pk Comprehens Canc Ctr, New York, NY USA
来源：
CANCER SCIENCE | 2023年 / 114卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-1185
引用
收藏
页码：597 / 597
页数：1
相关论文
共 50 条
  • [41] PROGESTERON RECEPTOR STATUS IN DETERMINING THE PROGNOSIS OF ESTROGEN RECEPTOR POSITIVE/HER2-NEGATIVE BREAST CARCINOMA
    Arslan, U. Yalcintas
    Bal, O.
    Ozatli, T.
    Helvaci, K.
    Esbah, O.
    Budakoglu, B.
    Uyeturk, U.
    Sonmez, O. U.
    Turker, I.
    Oksuzoglu, O. B.
    ANNALS OF ONCOLOGY, 2012, 23 : 105 - 105
  • [42] Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial
    Abdou, Yara
    Barlow, William E.
    Gralow, Julie R.
    Meric-Bernstam, Funda
    Albain, Kathy S.
    Hayes, Daniel F.
    Lin, Nancy U.
    Perez, Edith A.
    Goldstein, Lori J.
    Chia, Stephen K. L.
    Dhesy-Thind, Sukhbinder
    Rastogi, Priya
    Alba, Emilio
    Delaloge, Suzette
    Schott, Anne F.
    Shak, Steven
    Sharma, Priyanka
    Lew, Danika L.
    Miao, Jieling
    Unger, Joseph M.
    Tripathy, Debasish
    Hortobagyi, Gabriel N.
    Pusztai, Lajos
    Kalinsky, Kevin
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2025,
  • [43] Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer
    Fujii, T.
    Kogawa, T.
    Dong, W.
    Sahin, A. A.
    Moulder, S.
    Litton, J. K.
    Tripathy, D.
    Iwamoto, T.
    Hunt, K. K.
    Pusztai, L.
    Lim, B.
    Shen, Y.
    Ueno, N. T.
    ANNALS OF ONCOLOGY, 2017, 28 (10) : 2420 - 2428
  • [44] Alternative Palbociclib Dosing Schedules for Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer
    Go, Makiko
    Kimura, Michio
    Yamada, Shiori
    Kamei, Keitaro
    Noguchi, Yoshinori
    Usami, Eiseki
    Yoshimura, Tomoaki
    ONCOLOGY, 2024,
  • [45] Optimizing care for younger women with hormone receptor-positive, HER2-negative metastatic breast cancer
    de Boer, Richard
    Hui, Rina
    Lim, Elgene
    Yeo, Belinda
    Zdenkowski, Nicholas
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 3 - 14
  • [46] New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer
    Martinello, Rossella
    Genta, Sofia
    Galizia, Danilo
    Geuna, Elena
    Milani, Andrea
    Zucchini, Giorgia
    Valabrega, Giorgio
    Montemurro, Filippo
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (16) : 2179 - 2189
  • [47] Characterization of Weakly Hormone Receptor (HR)-Positive, HER2-Negative Breast Cancer and Current Treatment Strategies
    Poterala, Johanna E.
    Havighurst, Thomas
    Wisinski, Kari Braun
    CLINICAL BREAST CANCER, 2022, 22 (06) : 611 - 618
  • [48] Current Management and Future Perspectives of Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
    Gilchrist, Jenny
    SEMINARS IN ONCOLOGY NURSING, 2024, 40 (01)
  • [49] Treatment differences by race and age in metastatic hormone receptor-positive/HER2-negative breast cancer
    Abdou, Yara
    Ivory, Joannie
    Deal, Allison
    Wardell, Ally
    Wheless, Amy
    Dees, Claire
    Carey, Lisa
    CANCER RESEARCH, 2024, 84 (09)
  • [50] Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases
    Minetta C. Liu
    Javier Cortés
    Joyce O’Shaughnessy
    Cancer and Metastasis Reviews, 2016, 35 : 323 - 332
12345